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Abstract
Oncolytic virotherapies based on adenovirus 5 (Ad5) hold promise as adjunctive cancer therapies; however,
their efficacy when delivered systemically is hampered by poor target cell specificity and preexisting anti-Ad5
immunity. Ovarian cancer represents a promising target for virotherapy, since the virus can be delivered locally
into the peritoneal cavity. Both epidermal growth factor receptor (EGFR) and fibroblast growth factor receptor 1
(FGFR1) are overexpressed in the majority of human tumors, including ovarian cancer. To generate adenoviral
vectors with improved tumor specificity, we generated a panel of Ad5 vectors with altered tropism for EGFR
and FGFR, rather than the natural Ad5 receptor, hCAR. We have included mutations within AB loop of the
viral fiber knob (KO1 mutation) to preclude interaction with hCAR, combined with insertions in the HI loop to
incorporate peptides that bind either EGFR (peptide YHWYGYTPQNVI, GE11) or FGFR1 (peptides
MQLPLAT, M*, and LSPPRYP, LS). Viruses were produced to high titers, and the integrity of the fiber protein
was validated by Western blotting. The KO1 mutation efficiently ablated hCAR interactions, and significantly
increased transduction was observed in hCARlow/EGFRhigh cell lines using Ad5.GE11, while transduction
levels using Ad5.M* or Ad5.LS were not increased. In the presence of physiological concentrations of human
blood clotting factor X (hFX), significantly increased levels of transduction via the hFX-mediated pathway were
observed in cell lines, but not in primary tumor cells derived from epithelial ovarian cancer (EOC) ascites
samples. Ad5-mediated transduction of EOC cells was completely abolished by the presence of 2.5% serum
from patients, while, surprisingly, incorporation of the GE11 peptide resulted in significant evasion of neu-
tralization in the same samples. We thus speculate that incorporation of the YHWYGYTPQNVI dodecapeptide
within the fiber knob domain may provide a novel means of circumventing preexisting Ad5 immunity that
warrants further investigation.
Introduction
Ovarian cancer remains the fourth most commoncancer in women in the United Kingdom, with*7000
women diagnosed annually with the disease, and a mortality
rate of *4500 per annum. Patients often present with ad-
vanced disease because of the relatively nonspecific symptoms
associated with the disease, even in the early stages. Despite
recent therapeutic advances with the role of neoadjuvant
chemotherapy, changes in chemotherapy scheduling, bev-
acizumab,1 and PARP inhibitors,2 the outlook for advanced
ovarian cancer patients remains poor, with only small im-
provement in 5-year survival statistics over the last 20 years.
Standard treatments remain surgery and/or chemotherapy, and
despite good initial responses to chemotherapy, many tumors
rapidly develop resistance and progress into aggressive, plat-
inum-resistant forms. Therefore, there is a pressing need to
establish new therapeutics to combat the disease.
Oncolytic virotherapy is a promising adjunct to conven-
tional drug-based strategies for effective cancer therapies,
and has progressed into late-phase clinical trials.3 An on-
colytic herpes virus expressing GM-CSF has demonstrated
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higher response rates (26% vs. 6%) in malignant melanoma
with durable clinical responses, lasting for a minimum of 6
months, in 16% of patients, compared with 2% in the control
arm (GM-CSF treatment alone). These encouraging clinical
data have helped to re-energize the field of oncolytic viro-
therapy for cancer.
Among the repertoire of viruses under investigation as
oncolytics, human adenoviruses (Ad) have been widely
studied clinically and are generally well-tolerated and effi-
cient.4 Viruses can be grown and purified to exceptionally
high titers ( > 1013 viral particles/ml), and are readily ame-
nable to genetic modulation. Because of this versatility, they
represent the most commonly deployed virus clinically, and
are represented in 23% of gene therapy clinical trials. The
Ad phylogenetic tree is diverse, with 57 serotypes described
to date, divided into 7 species, A–G, based on receptor us-
age, hemagglutination patterns, serological cross reactivity,
and phylogenetic sequence alignments. The species C se-
rotype, adenovirus 5 (Ad5), is by far the most commonly
used, in both research and clinical trials. However, the pri-
mary Ad5 receptor, coxsackie and adenovirus receptor
(hCAR), is ubiquitously expressed in all organs of the human
body and on erythrocytes.5,6 Physiologically, its expression
pattern in organs co-localizes with tight junction marker,
zona occludens ZO-1, and is thus restricted to tight junc-
tions.7 Furthermore, there is increasing evidence suggesting
that expression of hCAR correlates negatively with tumor
progression in certain cancers.8–10
Targeted, tumor-specific delivery of Ad5-based viro-
therapy utilizing an unmodified hCAR is therefore chal-
lenging. Furthermore, since Ad5 is a common pathogen of
the respiratory tract, up to 90% of the population have high
titers of preexisting neutralizing antibodies (nAbs) against
Ad5, resulting in rapid and efficient elimination and neu-
tralization of Ad5-based vectors when delivered systemi-
cally.11,12 Such high level of preexisting immunity may
significantly hamper clinical translation and efficacy of Ad5
vectors, and consequently a great deal of effort has therefore
been placed on developing means to evade preexisting Ad5
immunity, either genetically13 or chemically, using hydro-
philic polymers such as pHPMA14 or PEG.15
Ovarian cancer frequently presents as stage 3 disease,
with peritoneal metastases. This disease state represents a
good potential target for intraperitoneal delivery of Ad-
based virotherapy. Local delivery precludes the requirement
for intravenous delivery, where interactions with multiple
cell types and a variety of serum proteins, including com-
plement-related proteins and blood clotting proteins, in
particular human blood clotting factor X (hFX), dictate
toxicity and tropism by ‘‘bridging’’ the virus to heparan
sulfate proteoglycans (HSPGs),16–19 abundant on hepato-
cytes. We hypothesized that combining mutations in the
Ad5 genome that abrogate hCAR interactions (KO1 muta-
tion), with insertion of peptide motifs into the viral fiber
knob that are selective for tumor-associated receptors,
would generate Ad vectors with improved tumor selectivity
in ovarian cancer. Previous studies have identified key
hCAR-interacting amino acids within the fiber AB loop at
Ser408 and Pro409.20 Furthermore, genetic re-targeting via
peptide insertion in the HI loop (after Thr541) has been
shown previously to be feasible.21 We selected three pre-
viously described peptide agonists, selected from phage
libraries, for genetic insertion into the Ad5 HI loop: a do-
decapeptide YHWYGYTPQNVI (GE11) binding to epider-
mal growth factor receptor (EGFR)22 and two heptapeptides,
MQLPLAT (M*)23 and LSPPRYP (LS),24 binding to fibroblast
growth factor receptor 1 (FGFR1). EGFR is overexpressed in
numerous tumor types, including lung, head and neck, colon,
pancreas, breast, ovary, bladder, and kidney cancer (reviewed
in ref.25). Approximately 30% of patients with both primary
and recurrent ovarian serous cancers demonstrate EGFR
overexpression.26 Similarly, the FGFR signaling pathway
has been shown to be upregulated in the majority of human
tumor types.27
Here, we report the successful production and in vitro
characterization of a suite of six novel, potentially tumor-
targetable recombinant Ad5 vectors. We evaluate their ability
to transduce cancer cell lines in vitro, and evaluate the effect of
hFX on their capacity to transduce both cell lines and primary,
epithelial ovarian cancer (EOC) cells isolated from ascites of
patients with ovarian cancer. Importantly, to best replicate the
clinical scenario, we evaluate the capacity of neutralizing se-
rum from ascites to neutralize Ad5 transduction of patient-
derived EOC in vitro and outline a potential role for peptide
incorporation in protecting Ad5-based vectors from nAbs.
Materials and Methods
Cell lines
CHO-K1 (Chinese hamster ovarian epithelial) and CHO-
CAR (CHO-K1 cell line transfected to express hCAR) cells
were grown in Dulbecco’s modified Eagle’s medium (DMEM)/
F12. T24 (human transitional cell carcinoma), SKOV3 (human
ovarian adenocarcinoma), and T-REx-293 (human embry-
onic kidney) cells were all grown in DMEM. RPMI 1640
medium was used for the culture of OVCAR3 (human
ovarian adenocarcinoma) cells. All cell culture media were
supplemented with 4mM L-Glutamine, 100U/ml penicillin,
100lg/ml streptomycin, and 10% fetal calf serum (FCS;
except 20% for OVCAR3). Dulbecco’s phosphate buffered
saline and 0.05% trypsin were used for subculture, all cells
were grown at 37C in a humidified atmosphere with 5% CO2,
and all reagents were purchased from Gibco or Thermo
Scientific (Paisley, UK).
Flow cytometry
An amount of 2.5·105 cells were incubated with primary
antibodies in triplicate: mouse anti-CAR clone RcmB (1:500;
Millipore, Watford, UK), mouse anti-EGFR clone H11 (1:200;
Thermo Scientific), mouse anti-FGFR1 clone M19B2 (1:100;
Abcam, Cambridge, UK), and normal mouse IgG control
(1:200; Santa Cruz Biotechnology, Heidelberg, Germany) on
ice for 1 h, followed by incubation with a secondary goat an-
timouse IgG Alexa Fluor647-conjugated antibody (1:500; Life
Technologies, Paisley, UK) for 30min on ice. The cells were
fixed in ice-cold 2% paraformaldehyde (PFA), 2· 104 gated
events were acquired on BD Accuri C6 (BD Biosciences) flow
cytometer, and data analysis was performed using FlowJo
software (Tree Star, Ashland, OR).
Primary cell culture from ovarian ascites
Permission for the collection and cultivation of cells from
ovarian ascites was granted through a Wales Cancer Bank
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application for biomaterials, reference WCB 14/004. All
patients gave written informed consent for the use of their
samples before collection. A 500ml total volume of ovarian
ascites (OAS) clinical samples were received from Velindre
Cancer Centre, Cardiff, and assigned as ‘‘group 2’’ according
to the stage of chemotherapy (1, pretreatment/chemo naı¨ve;
2, first-line chemo; 3, relapsed disease/platinum sensitive; 4,
relapsed disease/platinum resistant). Samples were given
codes OAS000 and OAS001 to retain anonymity. Fluids
were stored at 4C following collection from the patient, and
processed fresh within 2 hr. Primary EOC cells were sepa-
rated from the fluid by centrifugation at 1000 rpm for 5min.
The ascites fluid supernatant was stored at - 70C and the
cell pellet was treated twice with 2ml of red blood cell lysis
buffer (Sigma Aldrich, Gillingham, UK) according to the
manufacturer’s protocol. Two-thirds of the cell pellet was
aliquoted and frozen in 10% dimethyl sulfoxide and 90%
autologous supernatant at - 70C (passage 0) and 1/3 of the
cell pellet was resuspended into 10ml of RPMI 1640 me-
dium supplemented with 4mM Glutamax, 10% FCS, 100U/
ml penicillin, 100lg/ml streptomycin, 2.5lg/ml of ampho-
tericin B, and 10% of the autologous fluid supernatant and
cultured in a T25 cell culture flask. On the following day, the
cells were washed with PBS to remove the nonattached
contaminating cells and cell debris, and supplied with 10ml
of fresh medium. The cells were then subcultured or fed
every 3–5 days. Cell morphology was monitored by visual
examination under a light microscope throughout cell pas-
sages to exclude the possibility of fibroblast contamination.
3D modeling of the recombinant fiber proteins
The Ad5 fiber knob domains (GenPept: AP_000226.1)
with peptide insertions (scramble, GE11, M*, and LS) were
modeled by using SWISS-MODEL software28–30 (Basel,
Switzerland) and edited in PyMol Molecular Graphics soft-
ware (version 1.1eval, Schro¨dinger, LLC, NY) to assess the
spatial conformation of the inserted peptides in the context of
the homotrimeric knob structure. The models of the re-
combinant knobs are based on the wild-type Ad5 fiber knob
template (Protein Data Bank ID: 1KNB).
Generation of recombinant adenovirus genomes
The recombinant Ad5 genomes were based on luciferase
(Luc)-expressing replication-deficient (DE1/DE3) Ad5 (re-
ferred to as Ad5.Luc throughout the article).31 DNA se-
quences coding for EGFR and FGFR1 binding peptides
were inserted into the HI loop and a hCAR-binding ablating
KO1 mutation (S408E, P409A)32 was introduced into the
AB loop of Ad5 fiber knob. The Ad5 genome was modified
by homologous recombination in Escherichia coli strain
SW102 in a two-step process. First, an RPSL/neo selection
cassette was inserted into the region of interest, and then
replaced with DNA containing the appropriate sequence.
Selection cassettes and targeting peptide encoding DNA
fragments containing 70 bp homology arms were generated
by PCR using Expand Hi-Fi PCR system (Roche Applied
Science, East Sussex, UK). To generate the KO1 mutation, a
100 bp oligonucleotide (Sigma Aldrich) was used in the
second recombination step (Supplementary Table S1A;
Supplementary Data are available online at www.liebertpub
.com/hum). To confirm correct recombination, the DNA
constructs were sequenced (Supplementary Table S1B) in
an ABI Prism 3130 genetic analyzer (Applied Biosystems,
Warrington, UK). Cycle sequencing was performed ac-
cording to manufacturer’s instructions, with the exception
that 100 cycles were used instead of 25. Sequencing reac-
tions were purified using Performa DTR columns (Edge
Biosystems, Gaithersburg, MD) and sequence verification
was performed with CLC Main Workbench 6 software
(Qiagen, Manchester, UK).
Production and purification of Ad5 vectors
For virus generation, DNA was purified from 250ml
overnight culture (BacMax 100 kit; Macherey-Nagel, Duren,
Germany) and transfected into T-REx-293 cells in T25 tissue
culture flasks (Corning CellBIND, Amsterdam, The Nether-
lands) using Effectene (Qiagen). When cytopathic effect (CPE)
was complete, cell pellets were collected and virus extracted
with tetrachloroethylene (Fisher Scientific, Loughborough,
UK). To generate a working stock, this virus preparation was
used to infect 5· T150 confluent T-Rex-293 flasks. Cell
pellets were collected when CPE was complete (3–7 days
postinfection), and tetrachloroethylene extraction was per-
formed. This crude virus was purified by two rounds of cesium
chloride (CsCl) gradient ultracentrifugation and dialyzed
against buffer containing 10% glycerol, 10mM Tris-HCl (pH
7.8), 135mM NaCl, and 1mM MgCl2*6H2O to remove CsCl.
Viral titers were determined using microbicinchoninic acid
(BCA) assay (Pierce, Thermo Scientific) assuming that 1lg
protein equals 4·109 viral particles (vp).33
Western blotting to detect Ad5 fiber protein
The structural integrity of the Ad5 fiber proteins was
assessed by Western blotting. An amount of 5· 109 vp/virus
stock were run on ready-made 10% NuPAGE polyacryl-
amide gels (Invitrogen, Paisley, UK) by SDS-PAGE and
transferred to Hybond-P nitrocellulose membrane (GE
Healthcare Life Sciences, Little Chalfont, UK) by semidry
blotting. Nitrocellulose membranes were treated with 5ml
of Pierce Miser antibody extender (Thermo Scientific) for
10min and washing 7 times with distilled water. They were
then blocked in 5% milk in Tris-buffered saline containing
0.05% TWEEN-20 and 0.05% Triton X-100 (TBS-T)
overnight at 4C. The membrane was incubated in primary
anti-adenovirus fiber antibody 4D2 (1:2000) at 37C for 1 hr,
washed 5 times for 5min in TBS-T, and incubated in anti-
mouse IgG-HRP conjugate (1:2000; Insight Biotechnology
Ltd., Wembley, UK) for 1 hr at room temperature. After
washing a further 5 times for 5 min in TBS-T, the mem-
brane was incubated for 5 min in SuperSignal West Pico
Chemiluminescent substrate (Thermo Scientific), and
analyzed on GelDoc autoChemi camera (Ultra-Violet
Products Ltd., Cambridge, UK).
Transduction (luciferase) assays
The assay was performed using the Luciferase Assay
System kit, according to the manufacturer’s protocol (Pro-
mega UK Ltd., Southampton, UK) with slight modifications.
In brief, 24 hr before the experiment, cells were seeded on a
96-microwell plate (Nunc, Thermo Scientific) in complete
growth medium at a density of 2· 104 cells/well in triplicate
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and allowed to adhere overnight at 37C. Medium was then
removed, cells were washed with 200ll of PBS, and viruses
were added at doses of 1· 103, 5 · 103, and 1 · 104 vp/cell in
serum-free (serum - ) DMEM for 3 hr, after which the me-
dium was replaced with cell line-specific complete growth
media. Forty-eight hours postinfection the cells were lysed
with 1 · Cell Culture Lysis Buffer (Promega UK Ltd.) and
frozen at - 70C. The cells were thawed and prepared for
the analysis by Luciferase Assay System so that 20ll of cell
lysate was mixed with 100ll of luciferase assay reagent in a
white 96-well microwell plate and the luciferase activity in
relative light units (RLU) was then immediately measured
on a multimode plate reader (FLUOstar Omega; BMG
Labtech, Aylesbury, UK). Protein concentration in each well
of the sample plate was determined using microBCA assay
kit and bovine serum albumin (BSA) as a protein standard.
Luciferase activity from each well was then normalized for
total cellular protein (RLU/mg).
Transduction assays in the presence
of hFX and ovarian ascites fluid
Transduction assays in the presence of hFX were per-
formed essentially as described for the luciferase assay
above, with the exception of virus preincubation in serum -
medium supplemented with 10 lg/ml of hFX (Haematologic
Technologies, Cambridge Bioscience, Cambridge, UK) for
3 hr. All viruses were assayed at a dose of 5 · 103 vp/cell in
quadruplicate on OVCAR3 and T24 cell lines on a 96-well
plate (Nunc, Thermo Scientific). For the transduction neu-
tralization assays on primary EOC cells (passage 5), the
viruses were preincubated in serum - medium supplemented
with 2.5% of the OAS000 or OAS001 ascites supernatants
in triplicate on a 96-well plate. Ascites supernatant that
exhibited > 90% inhibition of transduction was considered
to be neutralizing, as described and validated previously for
serum neutralization assays.11
Statistical analysis
All figures were created in GraphPad Prism version
4.03 (GraphPad Software Inc., La Jolla, CA) and statistical
FIG. 1. Generation of recombinant cancer-targetable Ad5
vectors. (A) Overview of viral modification and production
using recombineering. (1) Design of the selection cassette,
(2) temperature-induced (42C) recombineering of the se-
lection cassette into Escherichia coli strain SW102 by
electroporation, (3) recombineering of the target sequence by
electroporation, (4) verification of the correct clone by se-
quencing, purification of DNA by maxiprep, and generation
of P1 virus stocks in permissive T-REx-293 cells, (5) prop-
agation of high titer P2 stocks, (6) purification of viral par-
ticles by CsCl gradient ultracentrifugation and dialysis, and
(7) titration by microBCA assay. (B) Amino acid sequence
alterations within the Ad5 fiber knob domain. Peptide se-
quences GE11, YHWYGYTPQNVI; M*, MQLPLAT; LS,
LSPPRYP; and scramble, LMTLAQP, were genetically in-
serted into fiber knob HI loop after Thr541. For the purpose
of native hCAR-binding ablation, KO1 mutation (S408E,
P409A) was introduced into the AB loop. (C) The inserted
peptides (shown in green) GE11, M*, LS, scramble, and the
HI loop (magenta) are highlighted. Inset: side view of the
fiber knob, showing native (gray) or mutated hCAR-binding
site (yellow). EGFR, epidermal growth factor receptor;
FGFR1, fibroblast growth factor receptor 1; hCAR, cox-
sackie and adenovirus receptor; KO1, hCAR-binding muta-
tion. (D) Verification of fiber integrity by Western blotting.
Color images available online at www.liebertpub.com/hum
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analysis performed using GraphPad Quickcalcs t-test calcu-
lator. Unless otherwise stated, data show the mean+SD of
n= 3–4 (specific n numbers are indicated in each figure leg-
end). Statistical significance was determined using two-tailed
unpaired t-test. *p-Value of < 0.05, **p< 0.01, ***p< 0.001,
ns= not statistically significant, p> 0.05.
Results
Generation of recombinant adenoviruses
We generated a panel of genetically modified Ad5 vector
genomes by rapid AdZ homologous recombineering method
(Fig. 1A), based on red lambda genetics.31 DNA sequences
encoding small peptide agonists of EGFR (36 bp) or FGFR1
(21 bp) were incorporated into the genome of replication-
deficient (DE1/DE3) Ad5 vector genomes. The introduced
modifications included insertion of GE11, M*, and LS
peptides into the HI loop of Ad5 fiber knob domain after
Thr541 (Fig. 1B and C) since this region has previously
been described as permissive of incorporation of small
peptide-based targeting ligands.21,34 A scrambled version of
the M* peptide (Ad5.scramble) was also created to act as a
negative control to ensure that the possible peptide-mediated
virus entry is dependent on the specific peptide sequence.
FIG. 2. Transduction efficiency of targeted Ad5 vectors and effect of human coagulation factor X (hFX). (A) hCAR
expression (green) as compared with isotype control normal mouse IgG (gray) on different cell lines, measured by flow
cytometry. (B) Transduction efficiency on CHO-K1 and CHO-CAR cell lines in serum-free medium (n = 4). (C) Trans-
duction efficiency on OVCAR3 cells (n = 3). (D) Transduction efficiency in serum-free medium (hFX - ) on T24 cell line
(n = 4). (E) Transduction efficiency on OVCAR3 and T24 cell lines in serum-free medium or supplemented with 10lg/ml of
human coagulation factor X (hFX) (n= 4). p-Values indicate comparison to the same virus in serum-free conditions (hFX - ).
(F) Transduction efficiency in presence of hFX ( + ) on T24 cell line (n= 4). p-Values indicate comparison to the same virus
in serum-free conditions (Fig. 2D). *p < 0.05, **p < 0.01, ***p < 0.001, ns= not statistically significant, p > 0.05. Error bars
represent SD. Color images available online at www.liebertpub.com/hum
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Detargeted Ad5 vectors were engineered by introduction of
KO1 point mutations (S408E, P409A) into the peptide-
modified re-targeted vectors (Fig. 1B and C) in an attempt to
abrogate cell entry via hCAR. All modifications were con-
firmed by sequencing to ensure that no mutation had oc-
curred within the region of homologous recombination.
Viruses could be grown to high titers (Fig. 1C), indicating
that peptide incorporation within the virion had no adverse
effects on viral infectivity.
Validation of fiber integrity following peptide insertion
The recombinant fiber monomers incorporating GE11, M*,
LS, and scramble peptide insertions were assessed for their
structural conformity by using the Ad5 fiber knob (Protein
Data Bank ID: 1KNB) as a template for the 3D models
(Fig. 1C). All 3D structures predicted the peptide insert to be
presented in a conformation compatible with receptor inter-
actions, extending outward from the fiber knob domain. All
recombinant Ad5 vectors showed a clear and distinctive single
band of *60 kDa on Western blotting (Fig. 1D), indicating
that peptide insertion within the fiber HI loop had not affected
the integrity of the resultant virion. The fiber monomer of
modified vectors migrated slightly slower than Ad5.Luc, re-
flecting the increase in size due to peptide incorporation.
Effect of peptide insertion on transduction in vitro
We evaluated the expression levels of hCAR, EGFR, and
FGFR1 on a range of cell lines, as well as on primary patient-
derived EOC cells, in order to select suitable model cell lines
for evaluating adenovirus re-targeting efficacy. The cells were
assessed for hCAR (Fig. 2A) and EGFR surface receptor
expression by flow cytometry, while FGFR1 expression
profiles were sourced from the literature (Table 1A). Four cell
lines—CHO-K1, CHO-CAR, OVCAR3, and T24—were se-
lected for further evaluation of transduction efficiency, based
on their hCAR, EGFR, and FGFR1 expression profiles. Pri-
mary, patient-derived EOC cells showed high levels of hCAR
and EGFR expression (Table 1B).
To confirm that the KO1 mutations (Ser408Glu and
Pro409Ala) could efficiently ablate hCAR-mediated cell
infectivity, we used model CHO-K1 (hCARlow) and CHO-
CAR (hCARhigh) cell lines. As expected, Ad5 efficiently
transduced CHO-CAR cells, but not CHO-K1 cells (Fig.
2B). Introduction of the KO1 abolished transduction of
Table 1. Analysis of Cell Surface Receptor Expression by Flow Cytometry
A. Receptor Expression on a Panel of Human Cancer Cell Lines
Cell lines Receptor expression
Name Origin hCAR EGFR FGFR1a
CHO-K1 Chinese hamster ovarian epithelial - - -
CHO-CAR CHO-K1 cell line expressing hCAR + - -
OVCAR3 Human ovarian adenocarcinoma + + +
T24 Human urinary bladder transitional cell carcinoma - + +
aFGFR1 expression on CHO-K1,49 OVCAR3,27 and T2450 cell lines.
B. Receptor Expression on Primary Epithelial Ovarian Cancer (EOC) Cells from Ascitic Fluid, at Passage 2
Primary EOC cells
Morphology Receptor expression
EGFR, epidermal growth factor receptor; EOC, epithelial ovarian cancer cells; FGFR1, fibroblast growth factor receptor; hCAR, human
coxsackie and adenovirus receptor.
Cell morphology was monitored to exclude the possibility of fibroblast contamination.
An amount of 2.5 · 105 cells were stained with primary antibodies mouse anti-hCAR (1:500, green), mouse anti-EGFR (1:200, blue),
mouse anti-FGFR1 (1:100, red), and isotype control normal mouse IgG (1:200, gray) in triplicate and detected with secondary goat
antimouse AlexaFluor647 conjugate (1:500). An amount of 2 · 104 gated events were recorded in FL-4 on BD Accuri B6 flow cytometer.
Color images available online at www.liebertpub.com/hum
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CHO-CAR cells (transduction levels similar to CHO-K1
cells), thus substantiating the involvement of these amino
acids in hCAR engagement (Fig. 2B).
In OVCAR3 cells (hCARhigh), levels of transduction for
Ad5.GE11, Ad5.M*, and Ad5.LS were decreased compared
with parental Ad5.Luc (Fig. 2C; p< 0.001). Surprisingly,
when the re-targeting peptides were presented in combina-
tion with hCAR ablation (KO1 vectors), we did not observe
any increase in transduction compared with the parental
Ad5.KO1 vector, implying a significant role for hCAR in
uptake of the recombinant viruses in these cells. In T24 cells,
which are hCARlow, incorporation of the GE11 peptide re-
sulted in a significant ( p< 0.01) *2-fold increase in trans-
duction compared with parental Ad5 (Fig. 2D), while no
increase in transduction was evident for either of the FGFR1-
targeted viruses, Ad5.M* or Ad5.LS (Fig. 2D). Since T24
cells are hCARlow, incorporation of the KO1 mutation did
not significantly change transduction efficiency of the pa-
rental vector. However, we were surprised that when KO1
mutation was combined with the GE11, M*, or LS insertion,
we failed to observe any detectable increases in levels of
transduction in this hCARlow/EGFRhigh/FGFhigh cell line.
Effect of physiological concentrations of hFX
on viral transduction levels
Interaction between the Ad5 hexon protein and the blood
clotting factor, hFX, has been shown previously to underlie
the hepatic tropism of intravenously administered Ad5, by
bridging the virus to HSPGs on hepatocytes. In order to
evaluate the effect, if any, of peptide incorporation in the
fiber protein on the capacity of our panel of viruses to infect
cancer cell lines in the presence of hFX, we performed
transduction assays in the presence and absence of physio-
logical hFX concentrations (10lg/ml). In hCARhigh OV-
CAR3 cells, Ad5.Luc transduction was unaffected by hFX
(Fig. 2E), with a modest *2-fold increase for Ad.KO1,
while in hCARlow T24 cells in which basal levels of trans-
duction were low (Fig. 2E), hFX significantly enhanced
transduction by 1–2 orders of magnitude, independent of
peptide insertion (Fig. 2F). Similar observations were made
for the control virus Ad5.KO1 on CHO-K1 and CHO-CAR
cell lines (data not shown), as hFX was capable of rescu-
ing transduction even in the case of fully abrogated hCAR-
mediated entry pathway. Therefore, for the generated vectors
to be useful for intravenous cancer therapeutics, additional
mutations will be required with the hexon protein to preclude
such interactions.
Neutralization of vector transduction
by ascitic fluid from ovarian cancer patients
To evaluate the potential of the generated vectors as
agents for local delivery in ovarian cancer, we obtained as-
citic fluid from patients with ovarian cancer, and established
primary EOC cell cultures. We performed transduction as-
says in OAS001 EOC cells. First, to establish the neutraliz-
ing antibody titers in ascitic fluid, we performed a series of
transduction experiments using Ad5.Luc in the presence of
doubling dilutions of ascitic fluid. We found that Ad5-
mediated transduction was inhibited by > 90% by*1/320 or
*1/80 dilution of OAS000 or OAS001, respectively, with
50% inhibition noted at dilutions of *1/640 and *1/160,
respectively (Fig. 3A). Based on these findings and previous
literature,11 we selected a neutralizing dose of 1/40 (2.5%)
for further studies. Viruses were preincubated in serum-
medium or medium supplemented either with hFX or with
2.5% cell-free ascitic fluid obtained from patients OAS000
FIG. 3. Transduction efficiency on primary epithelial
ovarian cancer (EOC) cells and vector neutralization by
ascitic fluid. (A) Inhibition of Ad5.Luc vector transduction
in the presence of increasing concentrations of ascitic fluid,
relative to serum - conditions. The approximate dilution that
neutralizes 50% and 90% of transduction is indicated with
dotted lines. (B) Vector transduction efficiency in four dif-
ferent virus–medium preincubation conditions: serum -
medium; with 10lg/ml of human coagulation factor X
(hFX + ); with 2.5% OAS000 supernatant; or with 2.5%
OAS001 supernatant. (C) Neutralizing effect of ovarian
ascites fluid supernatant on Ad5 vector transduction.
Transduction levels (%) are shown relative to Ad5.Luc
transduction in serum-free conditions. OAS000, ovarian
ascites supernatant patient #000; OAS001, ovarian ascites
supernatant patient #001. Error bars represent the SD (n = 3).
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and OAS001 consistent with previous studies evaluating the
nAb responses to Ad-based vectors from patient isolates.11,35
In the presence of hFX, only Ad5.KO1 demonstrated a
significant increase in transduction efficiency ( p = 0.002),
while hFX actually reduced transduction for Ad5.GE11
( p < 0.001) and Ad5.M* ( p = 0.022) compared with trans-
duction in the absence of serum or hFX (Fig. 3B and C). In
the presence of 2.5% ascitic fluid, levels of transduction
with Ad5 were reduced by 98.9% and 99.9% for OAS000
and OAS001, respectively (Fig. 3B and C), when compared
with serum-free conditions, consistent with the presence of
extremely high levels of preexisting nAbs in ascitic fluid
from these patients.36 However, when Ad5.GE11 was uti-
lized, we noted a significantly reduced pattern of neutrali-
zation, with transduction reduced to 89.2% and 42.4% of
that in the negative control (Ad.Luc in serum-free condi-
tions) for OAS000 and OAS001, respectively (Fig. 3B).
Thus, the presence of the 12-mer peptide was able to aug-
ment transduction by 81- and 707-fold, respectively, in the
presence of 2.5% neutralizing ascites, suggesting that pep-
tide incorporation was able to facilitate viral escape from
nAbs. A smaller, but significant response was also noted for
the 7-mer M* peptide, with transduction enhanced by 10-
and 4-fold in the presence of 2.5% neutralizing sera.
Discussion
Achieving tumor-selective delivery of adenoviral anti-
cancer vectors via the systemic route is highly problematic
because of the myriad of ‘‘off-target’’ interactions with cells
and proteins in the blood that dictate tropism and toxicity.
Ultimately, these dose-limiting interactions limit bioavail-
ability and efficacy. Ovarian cancer represents an ideal av-
enue for localized delivery of oncolytic virotherapies via the
peritoneal route, circumventing some of the difficulties of
delivery via the intravenous route.
In order to generate Ad vectors appropriate for localized
therapeutic applications in ovarian cancer, we generated a suite
of genetically modified vectors that combine mutations within
the Ad5 fiber protein that ablate interactions with the native
Ad5 receptor, hCAR, with peptide insertions which re-target
the recombinant viral vectors to receptors widely recognized
as being upregulated in tumors, namely, EGFR and FGFR1.
The selected peptides were YHWYGYTPQNVI (GE11) bind-
ing to EGFR22 and two heptapeptides, MQLPLAT (M*)23 and
LSPPRYP (LS),24 binding to FGFR1. To the best of our knowl-
edge, none of these peptides have been tested previously for
their ability to re-target a viral vector, though previous studies
for GE11 have demonstrated the capacity of this peptide to tar-
get nanoparticles,37 drugs,38 nonviral gene therapy vectors,39,40
and chemically modified Ad vectors41 via the EGFR receptor,
while the M* peptide has been utilized previously for targeted
delivery of nonviral vectors.23,42
We demonstrate that although we were able to generate
all the viral vectors to high titers, we were only able to
observe modest re-targeting from hCAR to EGFR using
Ad5.GE11 in the EGFRhighCARlow cell line, T24. We were
unable to observe any obvious re-targeting from hCAR to
FGFR1, using the Ad5.M*- or Ad5.LS-based vectors. Here,
we have utilized peptides selected previously by screening
linear bacteriophage libraries, for genetic re-targeting
strategies within a constrained viral protein. It would appear
that the constraints of the genetic approach imposing sec-
ondary structure on the targeting peptide may have reduced
the affinity of the selected peptide for the target receptor,
although previous strategies utilizing the same approach
have yielded success.43–47
A key limitation to the clinical deployment of Ad-based
medicines is the high level of preexisting immunity, esti-
mated at > 90% in some populations, which results in rapid
sequestration, neutralization, and elimination of virotherapy,
following systemic administration. The immunodominant
epitopes remain a subject of debate, with a number of
publications suggesting that Ad5 hexon hypervariable re-
gions (HVRs) are the major site of neutralization, at least
following intramuscular challenge. Indeed, several publi-
cations have elegantly demonstrated how genetically engi-
neering the Ad5 HVRs to exchange them for those from
rarely isolated serotypes results in viral vectors capable of
escaping immune recognition in preimmunized mice and
monkey models.13 However, following native respiratory
infection with Ad5, the Ad fiber protein is overexpressed
and secreted from epithelial cells to facilitate apical escape
of the virus, where is interacts with hCAR on the basolateral
membrane, disrupting the tight junction integrity and al-
lowing Ad5 virions to emerge apically.48 Therefore, it is
highly conceivable that a native Ad5 infection would result
in a predominantly antifiber response, as opposed to a dom-
inant antihexon response following intramuscular challenge
with Ad5.
Here, we demonstrate that the supernatant derived from
ovarian ascites at 2.5% readily neutralizes Ad5 infectivity36
by up to 3 logs. To our surprise, we also found that
Ad5.GE11 was highly resistant to this neutralization under
the same conditions, suggesting that the incorporation of the
12-mer peptide in the fiber knob domain impairs the capacity
of host antibodies in ascetic fluid to bind and neutralize the
Ad5-based vector. We noted a smaller but significant effect
for the Ad5.M* virus in evading preexisting immunity.
Ad5.M* displays a 7-mer FGFR1 interacting motif within
the fiber knob protein, and it is unclear whether the smaller
effect noted is because of the lack of expression of the
FGFR1 receptor in the EOC cells tested (which were
EGFR+ /FGFR1- ) or because of the smaller peptide motif
having a less marked effect on masking immunodominant
epitopes within the fiber knob domain.
Taken together, we propose that the peptide incorporation
within the fiber protein represents a potentially powerful
means for circumventing preexisting Ad5 immunity in
clinical populations and could represent promising means
for improving Ad5 efficacy clinically for local applications
such as in ovarian cancer.
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